Full text is available at the source.
Abstract
HD1916 may be therapeutically equivalent to semaglutide in reducing body weight.
- The evaluation focuses on body weight reduction in Chinese adults with obesity without diabetes.
- Comparison is made between HD1916 and the reference product semaglutide (Wegovy).
- The findings could inform treatment options for weight management in this population.
Simplified